Related Experiment Video
Updated: Jun 4, 2026

Anterior High-Resolution Optical Coherence Tomography in the Diagnosis and Therapeutic Monitoring of Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib
Michael C Lynch1, Renee Straub, David R Adams
1Pennsylvania State University College of Medicine, Hershey, PA, USA.
Abstract:
Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors. Commonly administered for the treatment of metastatic or unresectable hepatocellular carcinoma and advanced renal cell carcinoma, sorafenib has demonstrated remarkable survival benefits for those where curative surgery is not an option. Although generally having a mild side effect profile, sorafenib has been linked to a variety of dermatologic disorders, including most commonly acneiform rash, hand-foot-skin reactions, facial erythema, splinter subungual hemorrhages, alopecia or pruritus. The authors describe a case of sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient with hepatocellular carcinoma. This case adds to the growing literature suggesting a strong correlation between sorafenib and non-melanoma skin cancers including keratoacanthoma and squamous cell carcinoma. Routine dermatologic monitoring of these patients to ensure early detection is highly recommended. J Drugs Dermatol. 2011;10(3):308-310.
Insights
Sorafenib, a cancer drug, can cause skin cancers like squamous cell carcinoma and keratoacanthoma. Regular skin checks are crucial for patients undergoing sorafenib treatment to detect these side effects early.
Area of Science:
- Oncology
- Dermatology
Background:
- Sorafenib is a multikinase inhibitor used for advanced cancers like hepatocellular carcinoma and renal cell carcinoma.
- It offers survival benefits but can cause dermatologic side effects.
Observation:
- A case study details a patient with hepatocellular carcinoma who developed eruptive squamous cell carcinomas with keratoacanthoma-like features.
- These skin cancers were induced by sorafenib treatment.
Findings:
- The case supports a link between sorafenib and non-melanoma skin cancers, specifically squamous cell carcinoma and keratoacanthoma.
- Sorafenib's side effect profile includes various skin issues, with this case highlighting a rarer, more serious manifestation.
Implications:
- Routine dermatologic monitoring is recommended for patients on sorafenib.
- Early detection of sorafenib-induced skin cancers is vital for patient management and outcomes.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Abnormal Proliferation